BTIG downgraded Bionano Genomics to Neutral from Buy without a price target after the company announced its fourth workforce reduction since early 2023. The downgrade is driven by the ongoing challenging capital markets environment, particularly for small cap companies, the analyst tells investors in a research note. The firm cut estimates following the company’s reduced 2024 revenue outlook.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Bionano Genomics lays off 45% of staff, or 84 employees
- Bionano Genomics announces departure of CFO Gulsen Kama
- Bionano Genomics downgraded to Neutral from Buy at BTIG
- BioNano Genomics Restructures for Cost Efficiency and Cash Flow Optimization
- Bionano Genomics downgraded at Scotiabank on limited capital market visibility